Washington DC – there was so much noteworthy science on display at the annual meeting of the American Association for Cancer Research (AACR) on Monday that hard choices had to be made on what data to see in person.
Despite spending several hours in the poster sections of the exhibit hall, there was only the chance to see a small sample of the posters on display, each representing the culmination of months or years of work.
We will be writing our popular “Gems from the AACR Poster Hall” posts in due course.
It’s hard to convey how busy a meeting this is, unless you’ve been. Thousands of posters are shared, multiple sessions run in parallel, and that’s not to mention finding the time for 1:1 expert interviews. There is never much down time.
The challenge for many is that the more you know, the more you realise you don’t know. From a media perspective there is no shortage of questions to ask or important topics to cover.
Yet what really makes this meeting exciting is that it provides a glimpse of the future and the hope that offers. The cancer drugs of the future are being talked about at this meeting.
Today’s BSB post offers commentary around on what caught our attention at an extremely busy Monday at #AACR17 in Washington DC.